https://orcid.org/0000-0002-9023-581X
Figures & data
Figure 1. Plain language summary.
Figure 2. Evolution over time of meningococcal vaccination strategies in European countries.
Notes:a as Hib-MenC;b depending on the vaccine used, an additional dose (at 2 months) can be administered;c in 2 regions, a MenACWY dose is administered instead of the second dose of MenC vaccine at 12 months of age;d two introduction phases (private and public [funded] sector); dates for the public sector are given;e children born after the 1st of January2021 are included in the programme;f Liechtenstein follows the Swiss vaccination plan. MenC vaccination is recommended, but not part of the basic vaccination programme;g part of the complementary vaccination schedule, which is fully reimbursed since 2006;h in June 2021, the French National Authority for Health recommended that MenB vaccination is included in the national immunization programme;i starting from 2005 in some regions in Italy;j MenC vaccination was initially offered free of charge to all those requesting it by 31 March2017;k MenB vaccination is free of charge if the first dose is administered before 6 months of age. References supporting the information in this figure are provided in Supplement S1.
Figure 3. Evolution of serogroup-specific invasive meningococcal disease incidence and meningococcal vaccination strategies for 5 European countries.
IMD, invasive meningococcal disease; Men, meningococcal serogroup; M, months; N, number of cases; NIP, national immunization programme; Y, years. Note:Notification rates from the ECDC Surveillance Atlas [Citation21].
Figure 4. Distribution of reported serogroup-specific invasive meningococcal disease cases by age in European countries, 2014–2018
Men, meningococcal serogroup. Note:Data from the ECDC Surveillance Atlas [Citation21].
Figure 5. Introduction of routine meningococcal vaccination and current vaccination schedule in non-European countries
M, month (of age); Men, meningococcal serogroup; Y, year (of age). Notes:a varies by provinces and territories, in terms of schedule and implementation date;b on the basis of shared clinical decision-making;c two doses, 3 months apart;d if the child has not received the MenA polysaccharide vaccine between 2 and 4 years of age, he will receive the MenA plus MenC polysaccharide vaccine with a 3-year interval between the initial immunization and booster dose. References supporting the information in this figure are provided in Supplement S1.
Supplemental material